PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+57.5%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.46%
AUM
$4.47B
AUM Growth
+$4.47B
(+50%)
Cap. Flow
+$491M
Cap. Flow
% of AUM
10.98%
Top 10 Holdings %
Top 10 Hldgs %
48.45%
Holding
116
New
21
Increased
27
Reduced
22
Closed
11
Top Buys
| 1 |
Rhythm Pharmaceuticals
RYTM
|
$81.5M |
| 2 |
CRGX
CARGO Therapeutics
CRGX
|
$79.6M |
| 3 |
Spyre Therapeutics
SYRE
|
$54.4M |
| 4 |
Axsome Therapeutics
AXSM
|
$44.3M |
| 5 |
Biohaven
BHVN
|
$41.7M |
Top Sells
| 1 |
argenx
ARGX
|
$74M |
| 2 |
Immunovant
IMVT
|
$62.6M |
| 3 |
Roivant Sciences
ROIV
|
$44.6M |
| 4 |
Harmony Biosciences
HRMY
|
$32.6M |
| 5 |
Relay Therapeutics
RLAY
|
$16.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Verrica Pharmaceuticals
VRCA
$49.4M
| $52M | 1.16% |
7,099,182
+2,060,199
| +41% | +$15.1M |
|
27
Rocket Pharmaceuticals
RCKT
$358M
| $51.2M | 1.14% |
1,707,398
+189,931
| +13% | +$5.69M |
|
28
Apogee Therapeutics
APGE
$2.27B
| $51.1M | 1.14% |
1,827,901
| – | – |
|
29
Xenon Pharmaceuticals
XENE
$2.99B
| $50.7M | 1.13% |
1,100,748
+483,248
| +78% | +$22.3M |
|
|
RYZB
30
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $46.3M | 1.03% |
744,056
-32,749
| -4% | -$2.04M |
|
31
Cabaletta Bio
CABA
$144M
| $45.5M | 1.01% |
2,003,058
+870,567
| +77% | +$19.8M |
|
32
Crinetics Pharmaceuticals
CRNX
$3.26B
| $44.7M | 1% |
1,255,512
-8,220
| -0.7% | -$292K |
|
33
Sarepta Therapeutics
SRPT
$1.98B
| $43.6M | 0.97% |
451,873
+269,153
| +147% | +$26M |
|
34
Evolus
EOLS
$477M
| $41.7M | 0.93% |
3,963,424
+2,477,623
| +167% | +$26.1M |
|
35
Viridian Therapeutics
VRDN
$1.59B
| $37.7M | 0.84% |
1,730,212
+719,007
| +71% | +$15.7M |
|
36
Nautilus Biotechnolgy
NAUT
$80.7M
| $37.7M | 0.84% |
12,594,211
+3,483,060
| +38% | +$10.4M |
|
37
AbbVie
ABBV
$374B
| $36.9M | 0.82% |
+238,000
| New | +$36.9M |
|
38
Immatics
IMTX
$662M
| $36.8M | 0.82% |
3,491,500
| – | – |
|
39
Neurocrine Biosciences
NBIX
$13.5B
| $35.7M | 0.8% |
270,794
+111,552
| +70% | +$14.7M |
|
40
Madrigal Pharmaceuticals
MDGL
$9.7B
| $35M | 0.78% |
151,151
+26,514
| +21% | +$6.13M |
|
41
Astria Therapeutics
ATXS
$394M
| $30.8M | 0.69% |
4,004,070
+1,814,608
| +83% | +$13.9M |
|
42
Aldeyra Therapeutics
ALDX
$350M
| $30.2M | 0.67% |
8,593,586
-2,756,499
| -24% | -$9.68M |
|
43
ADMA Biologics
ADMA
$4.03B
| $29.1M | 0.65% |
6,433,369
-550,950
| -8% | -$2.49M |
|
44
Amylyx Pharmaceuticals
AMLX
$877M
| $27.5M | 0.61% |
1,869,125
-819,748
| -30% | -$12.1M |
|
|
FUSN
45
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $26.4M | 0.59% |
2,751,395
| – | – |
|
46
Tarsus Pharmaceuticals
TARS
$2.44B
| $26.3M | 0.59% |
1,296,416
| – | – |
|
47
Revolution Medicines
RVMD
$7.43B
| $23.5M | 0.52% |
818,882
-502,913
| -38% | -$14.4M |
|
48
Akero Therapeutics
AKRO
$3.65B
| $22.6M | 0.5% |
967,775
-651,650
| -40% | -$15.2M |
|
49
Orchestra BioMed
OBIO
$147M
| $22.2M | 0.5% |
2,432,089
| – | – |
|
50
Celcuity
CELC
$2.3B
| $21.6M | 0.48% |
+1,481,300
| New | +$21.6M |
|